Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, Biancone L, Bortoli A, Castiglione F, D'Incà R, Gionchetti P, Kohn A, Poggioli G, Rizzello F, Vecchi M, Cottone M; Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel Disease. Orlando A, et al. Among authors: armuzzi a. Dig Liver Dis. 2011 Jan;43(1):1-20. doi: 10.1016/j.dld.2010.07.010. Epub 2010 Sep 16. Dig Liver Dis. 2011. PMID: 20843756
Growth hormone in inflammatory bowel disease.
De Pascalis B, Bianchi A, Satta MA, Lupascu A, Mentella MC, Leo D, Fiore F, Fedeli P, Pontecorvi A, Pola P, Melina D, Gasbarrini A, De Marinis L, Armuzzi A. De Pascalis B, et al. Among authors: armuzzi a. Eur Rev Med Pharmacol Sci. 2006 Jan-Feb;10(1):13-6. Eur Rev Med Pharmacol Sci. 2006. PMID: 16494105 Review.
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G, Marrollo M, Sostegni R, Gasbarrini A, Peralta S, Prantera C. Kohn A, et al. Among authors: armuzzi a. Aliment Pharmacol Ther. 2007 Sep 1;26(5):747-56. doi: 10.1111/j.1365-2036.2007.03415.x. Aliment Pharmacol Ther. 2007. PMID: 17697208 Free article.
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.
Danese S, Mocciaro F, Guidi L, Scribano ML, Comberlato M, Annese V, Colombo E, Stefanelli T, Marzo M, Vangeli M, Pulitano' R, Manca A, Armuzzi A, Malesci A, Prantera C, Cottone M. Danese S, et al. Among authors: armuzzi a. Inflamm Bowel Dis. 2008 Aug;14(8):1168-70. doi: 10.1002/ibd.20426. Inflamm Bowel Dis. 2008. PMID: 18357580 Clinical Trial. No abstract available.
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A. Cottone M, et al. Among authors: armuzzi a. Clin Gastroenterol Hepatol. 2011 Jan;9(1):30-5. doi: 10.1016/j.cgh.2010.09.026. Epub 2010 Oct 15. Clin Gastroenterol Hepatol. 2011. PMID: 20951835
415 results